KR950702120A - 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis) - Google Patents

골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)

Info

Publication number: KR950702120A
Authority: KR; South Korea
Prior art keywords: high potency; day; thirty; potency phosphonate; phosphonate compound
Prior art date: 1992-06-30

Application number

KR1019940704866A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-30

Filing date

1994-12-30

Publication date

1995-06-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25422708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950702120(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-12-30 Application filed filed Critical

1995-06-19 Publication of KR950702120A publication Critical patent/KR950702120A/ko

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

KR1019940704866A 1992-06-30 1994-12-30 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis) KR950702120A (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US90660992A	1992-06-30	1992-06-30
PCT/US1993/005267 WO1994000129A1 (en)	1992-06-30	1993-06-04	Use of phosphonates for the treatment of osteoporosis

Publications (1)

Publication Number	Publication Date
KR950702120A true KR950702120A (ko)	1995-06-19

Family

ID=25422708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1019940704866A KR950702120A (ko)	1992-06-30	1994-12-30	골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)

Country Status (13)

Country	Link
EP (1)	EP0648120B1 (ko)
JP (2)	JP4481368B2 (ko)
KR (1)	KR950702120A (ko)
AT (1)	ATE161423T1 (ko)
AU (1)	AU659329B2 (ko)
CA (1)	CA2138367C (ko)
DE (1)	DE69316013T2 (ko)
DK (1)	DK0648120T3 (ko)
ES (1)	ES2111163T3 (ko)
GR (1)	GR3025792T3 (ko)
HU (1)	HUT70210A (ko)
MA (1)	MA22915A1 (ko)
WO (1)	WO1994000129A1 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2727629A1 (fr) *	1994-12-06	1996-06-07	Sanofi Sa	Trousse pour cycle de traitement de l'osteoporose
WO1996019998A1 (en) *	1994-12-28	1996-07-04	Gador S.A.	Bone mass anabolic composition comprising olpadronate
US5616571A (en) *	1995-06-06	1997-04-01	Merck & Co., Inc.	Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en)	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
EP1132088A3 (en) *	1997-07-22	2002-04-24	MERCK & CO. INC.	Method for inhibiting bone resorption
US5994329A (en)	1997-07-22	1999-11-30	Merck & Co., Inc.	Method for inhibiting bone resorption
AU2005227418B2 (en) *	1997-07-22	2008-05-29	Merck Sharp & Dohme Corp.	Method for inhibiting bone resorption
AU2007211965B2 (en) *	1997-07-22	2008-05-15	Merck Sharp & Dohme Corp.	Alendronate for use in the treatment of osteoporosis
US6432932B1 (en)	1997-07-22	2002-08-13	Merck & Co., Inc.	Method for inhibiting bone resorption
AR013994A1 (es) *	1998-10-30	2001-01-31	Gador Sa	Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
US6416737B1 (en) *	1998-11-19	2002-07-09	Board Of Trustees Of The University Of Arkansas	Increasing bone strength with selected bisphosphonates
EP1296689B3 (en)	2000-06-20	2013-02-13	Novartis AG	Method of administering bisphosphonates
CA2763775C (en)	2002-05-10	2014-01-07	F. Hoffmann-La Roche Ag	Bisphosphonic acids for the treatment and prevention of osteoporosis
JP2009530414A (ja) *	2006-03-17	2009-08-27	ザボードオブトラスティーズオブザユニヴァーシティーオブイリノイ	ビスホスホネート化合物及び方法
ITPA20070034A1 (it) *	2007-10-30	2009-04-30	Tetrapharm S R L	Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
US8882740B2 (en)	2009-12-23	2014-11-11	Stryker Trauma Gmbh	Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
TWI730039B (zh) *	2016-01-29	2021-06-11	日商富士藥品股份有限公司	新穎雙膦酸化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH27078A (en) *	1984-12-21	1993-02-01	Procter & Gamble	Pharmaceutical compositions containing geminal diphosphonates
IL77243A (en) *	1984-12-21	1996-11-14	Procter & Gamble	Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) *	1985-06-06	1988-08-02	The Procter & Gamble Company	Regimen for treating osteoporosis
IL84731A0 (en) *	1986-12-19	1988-05-31	Norwich Eaton Pharma	Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
IL86951A (en) *	1987-07-06	1996-07-23	Procter & Gamble Pharma	Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
DE4011777A1 (de) *	1989-04-14	1990-10-18	Ciba Geigy Ag	N-trisubstituierte aminoalkandiphosphonsaeuren

1993
- 1993-06-04 WO PCT/US1993/005267 patent/WO1994000129A1/en not_active Application Discontinuation
- 1993-06-04 JP JP50236694A patent/JP4481368B2/ja not_active Expired - Lifetime
- 1993-06-04 EP EP93914339A patent/EP0648120B1/en not_active Revoked
- 1993-06-04 DE DE69316013T patent/DE69316013T2/de not_active Revoked
- 1993-06-04 HU HU9403762A patent/HUT70210A/hu unknown
- 1993-06-04 AU AU44038/93A patent/AU659329B2/en not_active Ceased
- 1993-06-04 ES ES93914339T patent/ES2111163T3/es not_active Expired - Lifetime
- 1993-06-04 AT AT93914339T patent/ATE161423T1/de not_active IP Right Cessation
- 1993-06-04 DK DK93914339.2T patent/DK0648120T3/da active
- 1993-06-04 CA CA002138367A patent/CA2138367C/en not_active Expired - Fee Related
- 1993-06-29 MA MA23219A patent/MA22915A1/fr unknown
1994
- 1994-12-30 KR KR1019940704866A patent/KR950702120A/ko active IP Right Grant
1997
- 1997-12-30 GR GR970403268T patent/GR3025792T3/el unknown
2010
- 2010-01-15 JP JP2010006922A patent/JP2010106042A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
HUT70210A (en)	1995-09-28
EP0648120B1 (en)	1997-12-29
ATE161423T1 (de)	1998-01-15
DE69316013T2 (de)	1998-07-09
AU659329B2 (en)	1995-05-11
GR3025792T3 (en)	1998-03-31
DE69316013D1 (de)	1998-02-05
MA22915A1 (fr)	1993-12-31
CA2138367A1 (en)	1994-01-06
DK0648120T3 (da)	1998-01-19
AU4403893A (en)	1994-01-24
EP0648120A1 (en)	1995-04-19
JP4481368B2 (ja)	2010-06-16
ES2111163T3 (es)	1998-03-01
JPH07508278A (ja)	1995-09-14
JP2010106042A (ja)	2010-05-13
CA2138367C (en)	1998-09-22
WO1994000129A1 (en)	1994-01-06

Publication	Publication Date	Title
KR950702120A (ko)	1995-06-19	골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
ATE189400T1 (de)	2000-02-15	Knochenwachstumsfördernde zusammensetzung
MY103212A (en)	1993-05-29	Zinc-protamine-alpha interferon complex
RU94046316A (ru)	1996-10-20	Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
CA2124792A1 (en)	1993-06-24	Methods for the Treatment of Osteoporosis Using Bisphosphonates and Parathyroid Hormone
DK0600079T3 (da)	2002-04-15	Oral 1alpha-hydroxyprævitamin D
KR950702121A (ko)	1995-06-19	포스포네이트 및 비스테로이드계 소염 약물(nasid)을 함유하는 관절염 치료 조성물(compositions for the treatment of arthritis containing phosphonates and nsaids)
DK483285A (da)	1986-04-24	Farmaceutisk praeparat og anvendelsen af samme
IL99699A0 (en)	1992-08-18	Method of treating or preventing type 1 diabetes by oral administration of insulin
NO305581B1 (no)	1999-06-28	Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
EP0365779A3 (en)	1990-07-11	Cyclic grf-analogs ii
DK0389035T3 (da)	1994-02-14	Farmaceutisk præparat der indeholder en farmaceutisk egnet bærer og forbindelsen med strukturen (7alfa,17alfa)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-on
DE69429365D1 (de)	2002-01-17	Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
ES2026304A6 (es)	1992-04-16	Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
IT9020020A0 (it)	1990-04-12	"n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
DK0862454T3 (da)	2002-12-30	CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
NO874241D0 (no)	1987-10-09	Terapeutisk aktive salter.
DE3879837D1 (de)	1993-05-06	Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
NO945058L (no)	1995-02-28	Anvendelse av fosfonater for behandling av osteoporose
ES2101000T3 (es)	1997-07-01	Uso de bmy 14802 en el tratamiento de la ansiedad en pacientes con sindrome de abstinencia de benzodiazepinas.
IT1228135B (it)	1991-05-28	Composizione farmaceutica sterile per la somministrazione per via iniettabile della citidindifosfocolina veicolata tramite i liposomi
ATE74767T1 (de)	1992-05-15	Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
IT8848444A0 (it)	1988-10-12	Composizione farmaceutica comprendente inosina,acido p-acetammidobenzoico e zidovudina per il trattamento dell'aids e sindromi correlate

Legal Events

Date	Code	Title	Description
1994-12-30	PA0105	International application	Patent event date: 19941230 Patent event code: PA01051R01D Comment text: International Patent Application
1995-06-19	PG1501	Laying open of application
1998-06-03	A201	Request for examination
1998-06-03	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 19980603 Comment text: Request for Examination of Application
2000-02-25	E902	Notification of reason for refusal
2000-02-25	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20000225 Patent event code: PE09021S01D
2000-08-29	E701	Decision to grant or registration of patent right
2000-08-29	PE0701	Decision of registration	Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20000829
2001-05-29	NORF	Unpaid initial registration fee
2001-05-29	PC1904	Unpaid initial registration fee